The risk of hemorrhage in long-term treatment with aspirin and triflusal;El riesgo hemorragico en la toma prolongada de aspirina y triflusal

Revista de Neurologia

Volumn 27, Issue 160, 1998, Pages 951-955

  Alvarez Sabin J ^a,c   Matias Guiu J ^b   Galiano, L ^b   Codina Puiggros A ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiplatelet agents; Aspirin; Intracerebral hemorrage; Stroke; Triflusal

Indexed keywords

ACETYLSALICYLIC ACID; SEDERGINE; TRIFLUSAL; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CONTROLLED STUDY; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; RISK ASSESSMENT; BLEEDING; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; REVIEW; RISK FACTOR; SEX DIFFERENCE; TIME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CEREBRAL INFARCTION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SALICYLATES; SEX FACTORS; TIME FACTORS;

EID: 0032432157     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.27160.98266     Document Type: Article

References (43)

1. Mayo NE, Levy AR, Goldberg MS. Aspirin and hemorrhagic stroke. Stroke 1991; 22: 1213-4.
2. Adams HP, Bendixen BH. Low-versus-high-dose aspirin in prevention of ischemic stroke. Clin Neuropharmacol 1993; 16: 485-500.
3. Singh AK, Trotman BK. Use and safety of aspirin in the chemoprevention of colorectal cancer. J Assoc Acad Minor Phys 1998; 9: 40-4.
4. Álvarez Sabín J, Calvo G, Morros R. Prevención secundaria del ictus isquémico: efecto de la dosis de aspirina. Rev Neurol 1997; 25: 541-4.
5. Matías-Guiu J. Neuroepidemiología. Barcelona: JR Prous Editores; 1993.
6. Whisnant JP. Stroke: populations, cohorts and clinical trials. Oxford: Butterworth; 1993.
7. Álvarez Sabín J, Matías-Guiu J, Sumalla R, et al. Ischemic stroke in young adults. I. Analysis of the etiological subgroups. Acta Neurol Scand 1989; 80: 28-34.
8. Matías-Guiu J, Álvarez-Sabín J, Insa R, et al. Ischemic stroke in young adults. II. Analysis of risk factors. Acta Neurol Scand 1990; 81: 314-7.
9. Matías-Guiu J, Álvarez-Sabín J, Codina A. Estudio comparativo del efecto del ácido acetil-salicílico en dosis bajas y el triflusal en la prevención de eventos cardiovasculares en adultos jóvenes con enfermedad cerebrovascular isquémica. Rev Neurol 1997; 25: 1669-72.
10. Helgason CM, Tortorice KL, Winckler SR, Penney DW, Schuler JJ, Mc Clelland TJ, et al. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345-50.
11. Matías-Guiu J, Dávalos A, Pico M, et al. Low dose acetylsalicylic acid (AAS) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand 1997; 76: 413-21.
12. Dicken ML, Barnett HJM, Easton JD, Fields WS, Fuster V, Hachinski V, et al. Low dose aspirin and stroke 'It ain't necessarily so'. Stroke 1992; 23: 1395-9.
13. Buring JE, Bogousslavsky J, Dicken ML. Aspirin and stroke. Stroke 1998; 29: 885-6.
14. Barnett HMG, Kaste M, Meldrum BA, Eliaszin M. Aspirin dose in prevention of stroke. Stroke 1996; 27: 588-92.
15. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, et al. AICLA. Controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
16. UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988; 296: 316-20.
17. UK-TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-54.
18. The Steering Committee of the Physicians' Health Study Research Group. Preliminary report: finding from the aspirin component of the ongoing physicians' health study. N Engl J Med 1988; 318: 262-4.
19. The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989; 321: 129-35.
20. Peto R, Gray R, Collins R, Wheathley K, Hennekens CH, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-6.
21. The Ducht TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-6.
22. The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991; 338: 1345-9.
23. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
24. Francia E, Marín A, García-Rafanell J. Triflusal. Antithrombotic agent. Drug Fut 1978; 3: 225-8.
25. Triflusal, 15 años de experiencia farmacológica y clínica. Barcelona: Prous Science Editors; 1996.
26. Castellarnau C, Sancho MJ, Vila L, Albors M, Rutilant ML. Effects and interaction studies of triflusal and other salicylic derivates on cyclooxigenase in rats. Prostaglandins Leukot Essent Fatty Acids 1988; 31: 83-9.
27. De la Cruz JP, Mata JM, Sánchez de la Cuesta F. Triflusal vs aspirin on the inhibition of human platelet and vascular ciclooxigenase. Gen Pharmacol 1992; 23: 297-300.
28. Garcia-Rafanell J, Ramis J, Gómez L, Forn J. Effect of triflusal and other salicylic acid derivates on cyclic AMP levels in rat platelets. Arch Int Pharmacol Ther 1986; 284: 155-65.
29. Antiplatelet Trialist' Collaboration. Secondary prevention of vascular events by prolonged antiplatelet therapy. Br Med J 1988; 296: 310-31.
30. Antiplatelet Trialist' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
31. Kronnel RA, Hart RC, Monnolio TA, Talbert RL, Beauchamp NJ, Newman A. Aspirin use and incident stroke with cardiovascular health study. CHS Collaborative Research Group. Stroke 1998; 29: 887-94.
32. Rossouw JE, Clarke M, Davis M, Williams R. Occult gastrointestinal bleeding due to aspirin: comparison of two compounds. Rheumatol Rehabil 1976; 15: 31-4.
33. Rao G. Aspirin preparation and risk of GI bleeding. J Fam Pract 1997; 44: 242-3.
34. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-6.
35. Lanas AI, Arroyo MT, Esteva F, Cornudella R, Hirschowitz BI, Sainz R. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut 1996; 39: 654-60.
36. Whittle JR, Higgs GA, Eakins KE, et al. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980; 284: 271-3.
37. Cavalcanti FL, Fernández A, Miralles A, et al. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal and its deacetylated metabolite (HTB). Br J Pharmacol 1998 (In press).
38. McNeely YW, Goa KL. Triflusal. Drugs 1998; 55: 823-35.
39. De Castellarnau C, Sancho MJ, Vila L, et al. Effects and interaction studies of triflusal and other salicylic derivatives on cyclooxygenase in rats. Prostaglandins Leukot Essent Fatty Acids 1988; 31: 83-9.
40. De la Cruz JP, Mata JM, Sánchez de la Cuesta F. Triflusal versus aspirin on the inhibition of human platelets and vascular cyclooxygenase. Gen Pharmacol 1992; 23: 297-300.
41. García-Rafanell J, Ramis J, Gómez L, et al. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther 1979; 237: 343-50.
42. Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; 17: 1286-9.
43. Matías-Guiu J, Ferrer J, Álvarez Sabín J. Triflusal Aspirin Cerebral Infarction Prevention (TACIP study). Ongoing clinical trial. Cerebrovasc Dis 1998; 8 (Suppl 4): 86.